NuGene International, Inc. Presented To International Audience Of Skincare Leaders At FACE 2015

(Click here for details)
Nugene International, Inc. Advisory Board Member Dr. Vivian Bucay Addresses Skin Care at FACE Conference

IRVINE, CA--(Marketwired - June 08, 2015) - NuGene International, Inc. (“NuGene”) (OTCQB: NUGN), a developer, manufacturer and marketer of advanced skin and hair care lines utilizing adipose derived human stem cells and stem cell media, was recently introduced to an international audience of aestheticians, dermatologists and other skincare professionals at FACE 2015, one of the largest conferences in the world dedicated to facial aesthetics by Advisory Board member Dr. Vivian Bucay.

Dr. Bucay, of San Antonio, Texas, has been featured as a skin expert in several publications, including Allure, Cosmetic Surgery Times, Elle, More, Shape, Prevention, and Good Housekeeping. She has been featured as a keynote speaker across the globe on a wide scope of topics ranging from innovations in facial aesthetics to neuromodulators to cancer survival.

Dr. Bucay gave a presentation on emerging cosmeceuticals to the audience featuring NuGene’s line of stem cell derived products. She also participated as a panelist in two sessions regarding future topical treatments and nutritional supplements that affect skin aging.

FACE 2015, which ran from June 5th through the 7th in London, England, provided a forum for practitioners to meet the true experts who understand ingredients, formulations and the arguments behind competing concepts and brands. The three day forum focused on new topical approaches to preventing and treating signs and symptoms of ageing skin alongside the latest specific approaches to treating acne, rosacea and hyperpigmentation.

“This was a very effective introduction of NuGene’s products to the international market,” stated Dr. Bucay. “We had an audience of thought leaders and leading practitioners in the skin care industry and this was a perfect forum for NuGene’s proprietary products.”

Dr. Bucay is certified by the American Board of Dermatology and serves as a Clinical Assistant Professor in the Department of Physician Assistant Studies of the UT Health Science Center San Antonio. She is recognized nationally for her expertise in minimally invasive facial rejuvenation through the combined use of neuromodulators, injectable dermal fillers, and skin resurfacing. Considered to be one of the pre-eminent dermatologists in the United States, Dr. Bucay’s credentials span a wide scope of biomedical research, patient care, and medical education.

About NuGene International, Inc.

NuGene International, Inc. specializes in developing, manufacturing and marketing proprietary regenerative cosmeceutical and pharmaceutical products based on adipose derived human stem cell and human stem cell media. The US Department of Health and Human Services calls regenerative medicine the “next evolution of medical treatments.” The regenerative medical market which includes cosmeceuticals and pharmaceuticals was estimated at $7.2 Billion in the US in 2014 and is expected to rapidly grow in the coming years according to RNCOS Business Consultancy Services Global Cosmeceuticals Market report. NuGene’s cosmeceutical and pharmaceutical products are based on proprietary stem cell based regenerative formulations derived from non-controversial, adult human stem cell derived media obtained from adipose tissue. NuGene’s exclusive products combine its in-house advancements, proprietary technologies, and patent pending formulations. The company has four patents pending covering 15 unique applications and inventions. NuGene’s goal is to leverage its knowledge and expertise to develop age defying cosmeceutical skincare and hair care products in addition to pharmaceutical products based on the same regenerative science platform.

Forward-Looking Statements

This release contains forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to the possibility that some or all of the matters and transactions considered by NuGene International may not proceed as contemplated, and by all other matters and assumptions specified in NuGene’s filings with the Securities and Exchange Commission, especially those risks and other matters described under “Risk Factors” within NuGene’s Form 10-Q filed with the Commission on May 15, 2015. These statements are made based upon current expectations that are subject to risk and uncertainty. NuGene does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information.